Streetbeat News

RLFTF

Relief Therapeutics Holding SA

https://relieftherapeutics.com/c

Industry

Medicinal and Botanical Manufacturing

Open

4.25

Mkt cap

56M

Volume

100

High

4.50

P/E Ratio

-1.11

52-wk high

7.66

Low

4.25

Div yield

N/A

52-wk low

1.10

Relief Therapeutics announced positive results from a clinical trial of PKU GOLIKE, a protein substitute for phenylketonuria (PKU) patients. The trial showed improved metabolic control during prolonged fasting, potentially increasing awareness and adoption of PKU GOLIKE.

Portfolio Pulse from

December 16, 2024 | 6:30 am

Relief Therapeutics plans to file a Form 15F to terminate its SEC reporting obligations while maintaining its listing on the SIX Swiss Exchange, U.S. ADR program, and U.S. OTCQB quotation.

Portfolio Pulse from

December 13, 2024 | 10:45 pm

Relief Therapeutics announced positive final results from a clinical trial of RLF-TD011 for treating epidermolysis bullosa, a rare genetic skin condition. The trial showed promising effects on microbiome diversity in wounds of EB patients.

Portfolio Pulse from

November 11, 2024 | 6:30 am

Eton Pharmaceuticals has acquired exclusive U.S. rights to PKU GOLIKE from Relief Therapeutics. The transaction is expected to be accretive to Eton's earnings in 2024, with PKU GOLIKE estimated to reach peak sales of over $10 million annually in a U.S. PKU medical formula market worth approximately $100 million annually.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 6:29 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.